Physician profile
Eric Alan Kirk
NPI 1154530087
$1,967.41
in general payments reported to CMS, 2019-2025
26 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.56 · 2020: $226 · 2021: $71.78 · 2022: $170 · 2023: $314 · 2024: $643 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361 · Travel and Lodging: $31.38 · Education: $21.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.67 |
| Travel and Lodging | $31.38 |
| Education | $21.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $324.84 | 2019-2025 | Lokelma, Farxiga |
| Nxstage Medical, INC. | $260.22 | 2025 | Liberty Select Cycler, Nxstage System One |
| Otsuka America Pharmaceutical, INC. | $213.95 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $196.63 | 2021-2024 | |
| Lilly USA, LLC | $113.25 | 2023-2025 | Jardiance |
| Bard Peripheral Vascular, INC. | $104.97 | 2020 | |
| Akebia Therapeutics INC | $83.66 | 2020-2025 | Vafseo |
| Vifor Pharma, INC. | $82.85 | 2019-2024 | Veltassa |
| Mallinckrodt Hospital Products INC. | $80.47 | 2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.26 | 2023-2024 | Jardiance |
| Amgen INC. | $72.43 | 2021-2025 | Tavneos |
| Glaxosmithkline, LLC. | $56.75 | 2023-2024 | Benlysta, Jesduvroq |
| Calliditas Therapeutics US INC. | $53.57 | 2022-2023 | Tarpeyo |
| Travere Therapeutics, INC. | $50.00 | 2023-2024 | |
| Fresenius USA Marketing, INC. | $35.02 | 2023 | Velphoro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $32.67 | 2019-2021 | |
| Daiichi Sankyo INC. | $30.18 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $25.02 | 2025 | |
| Boston Scientific Corporation | $21.45 | 2022 | |
| Ani Pharmaceuticals, INC. | $21.14 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $18.07 | 2020 | |
| Aurinia Pharma U.S., INC. | $14.01 | 2024 | Lupkynis |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.